Genmab ADR (NASDAQ:GMAB) does about 1.10M shares in volume on a normal day but saw 1133542 shares change hands in the recent trading day. The company now has a market cap of 13.78B USD. Its current market price is $21.70, marking a decrease of -0.64% compared to the previous close of $21.84. The 52 week high reached by this stock is $32.88 whilst the lowest price level in 52 weeks is $20.34. The script in recent trading has seen the stock touch a high of $53 and a low of $31.
Genmab ADR (GMAB) has a 20-day trading average at $21.54 and the current price is -34.00% off the 52-week high compared with 6.69% distance from its 52-week low. The 50-day simple moving average of the closing price is $22.60 and its 200-day simple moving average is $26.68. If we look at the stock’s price movements over the week, volatility stands at 1.29%, which increases to 1.86% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 48.25 to suggest the stock is neutral.
8 analysts observing the Genmab ADR (GMAB) stock have set the 12-month price targets for the company’s shares at between $31 and $53. The consensus objective for the share price is $35.71, suggesting that the stock has a potential upside of 39.23% over the period. The median price target is 52.83% away from the current levels at $46.
FactSet Research has provided data showing that 8 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 8 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The current price level is 0.75%, -4.00%, and -18.67% away from its SMA20, SMA50, and SMA200 respectively, with the GMAB price moving above the 50-day SMA on current market day. Genmab ADR (GMAB) stock is up 4.38% over the week and -3.81% over the past month. Its price is -31.85% year-to-date and -32.12% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/30/2024, with the company’s earnings per share (EPS) of 0.14 below consensus estimates by -0.14. The company’s next earnings report forecasts estimating quarterly EPS at 0.37 and 1.3 for whole year. Expected sales for next quarter are $4.93B, which analysts say will come at $21.37B for the current fiscal year and next year at $24.76B. In addition, estimates put the company’s current quarterly revenue at an average of $6.35B.
Its 12-month price target is $46. To reach the target analysts have set, the stock logically needs to grow 39.23 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $31, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $53.
Outstanding shares total 635.14M with insiders holding 0.01% of the shares and institutional holders owning 8.41% of the company’s common stock. The company has a return on investment of 13.73% and return on equity of 14.67%. The price to earnings ratio (P/E ratio) amounts to 20.90 while the forward price to earnings ratio is 15.94. The beta has a value of 0.96. Price to book ratio is 2.88 and price to sales ratio is 4.80.
